hVIVO PLC (AIM:HVO) chief executive Mo Khan speaks to Proactive after announcing the signing of a £5.2mln contract with a biotech company in the Asia Pacific region to test the latter's respiratory syncytial virus (RSV) vaccine candidate.
Khan says that the deal is the first hVIVO has signed in Asia in a decade, and is the result of the research company's increasing focus on growing its sales in the region